Boulder, Colorado, November 10, 2005 --- Glucon ( www.glucon.com ) announced today the recent trial results of its flagship product, Aprise, a continuous, non-invasive, glucose monitoring device. The data was presented by Glucon V.P. of R&D Dr. Benny Pesach at the Diabetes Technology Society Standards Workshop on November 10, 2005 at the Fifth Annual Diabetes Technology Meeting in San Francisco.

“Three different protocols were employed to test Aprise. In the first protocol rapid glucose variations were induced by venous infusion of dextrose solution and insulin. In the second protocol, the glucose level was increased by drinking a glucose solution and decreased by the diabetic subject’s regular medications. And in the third protocol the glucose level was raised with a regular meal and decreased again by the diabetic subject’s regular medications. Thirty subjects participated in the studies. The prospective results were a Mean Absolute Relative Deviation of 19%,” explained Dr. Benny Pesach.

Glucon will also be presenting clinical data at its exhibition booth (Hall 14, Booth B24-3) at Medica, the 37th World Forum for Medicine at the Düsseldorf Trade Fair Centre, Messeplatz, November 16-19, 2005 in Düsseldorf, Germany.

“There are several companies in the glucose monitoring space racing to develop an accurate, non-invasive system. Data collected with Glucon’s Aprise showed that the technology has surpassed that of the competition in terms of accuracy and speed. Glucon’s Aprise provides a glucose measurement every three seconds. It is also light weight, compact, comfortable, impressively accurate and the most clinically advanced,” said Glucon President Mr. Ron Nager.

Glucon also announced today that the Company has secured an option to license several photoacoustic technology patents, granted to a group of scientists at the University of Texas Medical Branch in Galveston, TX.

About Glucon
Glucon ( www.glucon.com ) is developing a continuous, non-invasive, blood glucose (sugar) monitoring device for home and clinical use. Glucon was founded in 2000 by two Israeli scientists, Company President Ron Nagar and V.P. of R&D, Dr. Benny Pesach. Glucon’s technology enables blood glucose measurements to be accessed directly from inside the blood vessel. The company’s flagship product, Aprise, is currently undergoing extensive clinical trials. Seed financing was provided by InnoMed Ventures. Additional investors include Giza Venture Capital, Infinity Venture Capital Fund, Ascend Technology Ventures, and several others.

Press Contact: Marjie Hadad, Media Liaison, Glucon, marjie@glucon.com  or +972-54-536-5220.